title: Adalimumab-induced pulmonary sarcoidosis not progressing upon treatment with etanercept.
abstract: Tumor necrosis factor alpha (TNF-α) inhibitors effectively treat sarcoidosis, but can, paradoxically, induce sarcoidosis. The TNF-α inhibitor etanercept is most commonly associated with paradoxical sarcoidosis, which has previously been reported to be resolved by adalimumab. However, we describe the case of a patient with ankylosing spondylitis and adalimumab-induced sarcoidosis not aggravated by switching to etanercept, thus indicating that etanercept could be a treatment option for patients who develop paradoxical sarcoid-like reactions after treatment with other TNF-α inhibitors.
authors.affiliation: Korea University College of Medicine, Seoul, Korea.|Division of Rheumatology, Department of Internal Medicine, Korea University Guro Hospital, 148, Gurodong-ro, Guro-gu, 08308, Seoul, Korea.
authors.forename: J H
authors.initials: JH
authors.lastname: Jung
authors.affiliation: Korea University College of Medicine, Seoul, Korea.|Division of Rheumatology, Department of Internal Medicine, Korea University Guro Hospital, 148, Gurodong-ro, Guro-gu, 08308, Seoul, Korea.
authors.forename: J-H
authors.initials: JH
authors.lastname: Kim
authors.affiliation: Korea University College of Medicine, Seoul, Korea. gsong@kumc.or.kr.|Division of Rheumatology, Department of Internal Medicine, Korea University Guro Hospital, 148, Gurodong-ro, Guro-gu, 08308, Seoul, Korea. gsong@kumc.or.kr.
authors.forename: G G
authors.initials: GG
authors.lastname: Song
mesh_terms: D000068879:Adalimumab / Q000009:adverse effects*; D000328:Adult; D018450:Disease Progression; D057915:Drug Substitution / Q000009:adverse effects / Q000379:methods; D000068800:Etanercept / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D017565:Sarcoidosis, Pulmonary / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000068879:Adalimumab; D000068800:Etanercept
keywords: Adalimumab; Etanercept; Paradoxical response; Pulmonary sarcoidosis; Tumor necrosis factor-α